Skip to main content

Subarachnoid Hemorrhage, Aneurysmal

5
Pipeline Programs
9
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Cumberland Pharmaceuticals
1 program
1
Telavancin InjectionPhase 41 trial
Active Trials
NCT06119061Recruiting20Est. Dec 2026
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
2 programs
1
1
Ketamine HydrochloridePhase 2/31 trial
GSK2256294Phase 1/2
Active Trials
NCT05032118Withdrawn0Est. Apr 2023
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK2256294Phase 1/2
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
Remote ischemic preconditioningPhase 11 trial
Active Trials
NCT01158508Completed20Est. Jul 2014
Edwards Lifesciences
1 program
- Non-Invasive Near-infrared SpectroscopyN/A1 trial
Active Trials
NCT06932640Not Yet Recruiting120Est. Dec 2028
Labcorp
LabcorpBURLINGTON, NC
1 program
Gamma Entrainment StimulationN/A1 trial
Active Trials
NCT06346015Unknown60Est. Mar 2025
ADEL
ADELKorea - Seoul
1 program
Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid HaemorrhageN/A1 trial
Active Trials
NCT03010709Unknown100Est. Feb 2022
Verona Pharma
Verona PharmaUK - London
1 program
Standard management according to international/national guidelinesN/A1 trial
Active Trials
NCT04945603Recruiting800Est. Dec 2028
electroCore
electroCoreNJ - Rockaway
1 program
gammaCoreN/A1 trial
Active Trials
NCT05103566Recruiting25Est. Apr 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Cumberland PharmaceuticalsTelavancin Injection
Oregon TherapeuticsKetamine Hydrochloride
Angeles TherapeuticsRemote ischemic preconditioning
Edwards Lifesciences- Non-Invasive Near-infrared Spectroscopy
LabcorpGamma Entrainment Stimulation
electroCoregammaCore
Verona PharmaStandard management according to international/national guidelines
ADELMultimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage

Clinical Trials (8)

Total enrollment: 1,145 patients across 8 trials

NCT06119061Cumberland PharmaceuticalsTelavancin Injection

Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage

Start: Jul 2024Est. completion: Dec 202620 patients
Phase 4Recruiting
NCT05032118Oregon TherapeuticsKetamine Hydrochloride

Pilot Study of Ketamine Sedation for Aneurysmal Subarachnoid Hemorrhage

Start: Apr 2023Est. completion: Apr 20230
Phase 2/3Withdrawn
NCT01158508Angeles TherapeuticsRemote ischemic preconditioning

Remote Ischemic Preconditioning in Subarachnoid Hemorrhage

Start: Apr 2010Est. completion: Jul 201420 patients
Phase 1Completed
NCT06932640Edwards Lifesciences- Non-Invasive Near-infrared Spectroscopy

Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)

Start: Jul 2026Est. completion: Dec 2028120 patients
N/ANot Yet Recruiting
NCT06346015LabcorpGamma Entrainment Stimulation

Gamma Entrainment Stimulation for Cognitive Dysfunction After aSAH

Start: Apr 2024Est. completion: Mar 202560 patients
N/AUnknown
NCT05103566electroCoregammaCore

Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage

Start: Oct 2022Est. completion: Apr 202625 patients
N/ARecruiting
NCT04945603Verona PharmaStandard management according to international/national guidelines

Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group

Start: May 2021Est. completion: Dec 2028800 patients
N/ARecruiting
NCT03010709ADELMultimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage

Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage

Start: Feb 2017Est. completion: Feb 2022100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,145 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.